WuXi XDC Cayman Inc
WuXi XDC Cayman Inc is a pharmaceutical company that provides drug discovery and development services, primarily serving the biopharmaceutical industry.
Business. WuXi XDC Cayman Inc is a healthcare company operating in the pharmaceuticals industry, primarily engaged in pharmaceutical activities. The firm is listed on the Hong Kong Stock Exchange under the ticker symbol 2268.HK. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the pharmaceuticals and medical research sector.
Analyst recommendations
20 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
WuXi XDC Cayman Inc is a healthcare company operating in the pharmaceuticals industry, primarily engaged in pharmaceutical activities. The firm is listed on the Hong Kong Stock Exchange under the ticker symbol 2268.HK. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the pharmaceuticals and medical research sector.
WuXi XDC Cayman Inc has a market capitalization of 72.5 billion CNY, with a current market price of 57.5 CNY per share. The company's shares outstanding are 1.26 billion, with no dilution observed between basic and diluted shares. Analysts have assigned a mean price target of 78.61 CNY and a median price target of 82.00 CNY, indicating a potential upside of 36.7% and 42.7%, respectively.
The company's profitability and return metrics are not available in the current dataset, which limits the ability to compare its performance against industry benchmarks. However, the mean recommendation of 1.65 from analysts suggests a generally positive outlook, with 7 strong-buy and 13 buy ratings. The absence of hold or sell ratings further reinforces the positive sentiment among analysts.
Geographic and segment exposure data are not disclosed in the available source documents, making it difficult to assess the company's revenue concentration or regional dependencies. This lack of transparency could pose a risk to investors seeking to understand the company's exposure to specific markets or product lines.
The company's growth trajectory is not quantified in the current dataset, but the analyst price targets suggest a potential for significant appreciation in the near term. The absence of historical revenue data limits the ability to assess the company's growth rate or sustainability.
Risk factors include the inability to assess liquidity risk due to the absence of balance-sheet inputs and no going-concern language in source documents. The dilution risk is currently rated as low, with no near-term dilution pressure observed.
Recent events and filings are not detailed in the available source documents, which limits the ability to assess the company's recent performance or strategic direction. Investors should monitor upcoming filings and earnings reports for more detailed insights.
- WuXi XDC Cayman Inc is a pharmaceutical services company with a strong analyst outlook, as evidenced by a mean price target of 78.61 CNY and a median price target of 82.00 CNY.
- The company has no dilution between basic and diluted shares, indicating a stable capital structure.
- Analysts have assigned a mean recommendation of 1.65, with 7 strong-buy and 13 buy ratings, suggesting a generally positive sentiment.
- The company's profitability and return metrics are not available, limiting the ability to compare its performance against industry benchmarks.
- The absence of balance-sheet inputs and no going-concern language in source documents makes it difficult to assess liquidity risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥5.94B, +46,7% YoY; Operating income +43,4% YoY.
- ▍Revenue ¥5.94B, +46,7% YoY
- ▍Operating income +43,4% YoY
- ▍Net income +38,4% YoY
- ▍Free cash flow +217,2% YoY
- ▍Net margin 24.9%
Revenue ¥4.05B, +90,8% YoY; Operating income +239,4% YoY.
- ▍Revenue ¥4.05B, +90,8% YoY
- ▍Operating income +239,4% YoY
- ▍Net income +277,2% YoY
- ▍Free cash flow −65,0% YoY
- ▍Net margin 26.4%
Revenue ¥2.12B, +114,4% YoY; Operating income +81,3% YoY.
- ▍Revenue ¥2.12B, +114,4% YoY
- ▍Operating income +81,3% YoY
- ▍Net income +82,1% YoY
- ▍Free cash flow −1 190,6% YoY
- ▍Net margin 13.4%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,66 |
| Revenue | —no estimate | —no estimate | 8,2B CNY |
| Operating income | —no estimate | —no estimate | 2,6B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- WuXi XDC Cayman Inc Market data — financials · 2026-05-26
- WuXi XDC Cayman Inc Market data — analyst estimates · 2026-05-26
- WuXi XDC Cayman Inc Market data — ESG · 2026-05-26